Barty Medical Secures Nearly RMB 200 Million in Series D Financing to Accelerate Commercialization & Global Expansion of Vascular Interventional Innovations

Recently, Zhejiang Barty Medical Technology Co., Ltd. (Barty Medical) announced the completion of its Series D financing round totaling nearly RMB 200 million. The round was led by CDF-Capital, with participation from Zhejiang’s '4+1' Biopharma & High-End Medical Device Industry Fund, Efung Capital and Nanjing Zhongyiren Investment Limited Company, alongside individual industrial investors. Existing shareholder Jingle Capital increased its stake, with Springhill Fund also providing financing support.

Proceeds from this financing will primarily support the commercial rollout and clinical evidence collection for the company’s globally leading third-generation constrained drug-coated balloons, the construction of a new smart manufacturing base, and R&D for next-generation innovative vascular interventional devices. As a full-platform player in vascular intervention, Barty Medical has rapidly commercialized its product portfolio in recent years. Its newly launched innovative products have repeatedly won bulk procurement bids across China, while the firm continues to expand overseas sales. The company is also advancing strategic financing initiatives to further scale global operations and push forward capital market development.

Founded in August 2015 and headquartered in Hangzhou Biomedical Port, China, Barty Medical focuses on the R&D, production and sales of cutting-edge devices for pan-vascular intervention. It holds multiple prestigious credentials, including National High-Tech Enterprise, National Specialized, Refined, Differential & Innovative "Little Giant" Enterprise, and Zhejiang Provincial Outstanding Tech SME. Driven by lean manufacturing and technological innovation, the company has long focused on vascular intervention. To date, it has obtained NMPA registration certificates for 19 medical devices in China, building a comprehensive solution portfolio covering vascular access, luminal preparation and implant-free drug therapy. A pipeline of first-in-class and China-first products is also set to launch in the years ahead.

Rising population aging and a growing sub-health population have pushed up the incidence of vascular diseases and related surgical volumes, fueling robust market demand for vascular interventional devices. Compared with developed economies, China’s vascular intervention sector is a late starter yet boasts a large patient base and strong growth momentum. According to the 2024 Report on Cardiovascular Health and Diseases in China and other public statistics, the country has roughly 76 to 78 million patients living with coronary, peripheral, neurological and other vascular conditions. In 2024, around 3.05 million vascular interventional procedures were performed nationwide, translating to a surgical penetration rate of merely 4%, which points to immense upside for the pan-vascular intervention market. Major sub-sectors including coronary, peripheral and neuro intervention have maintained solid double-digit annual growth of 10% to 30% in surgical volumes.

To meet surging clinical needs, China has scaled up volume-based procurement programs to make high-quality medical devices accessible to more patients. Leveraging its robust lean manufacturing capabilities and full-spectrum vascular intervention solutions, Barty Medical has secured bids for all its core products including vascular access devices, balloon catheters and drug-coated balloons in national and regional bulk procurement initiatives, cementing its leading position in China’s peripheral vascular intervention market. Vascular introducer sheaths, an essential tool to establish surgical access, have long been dominated by foreign brands. Global trade disruptions and public health crises have also posed risks to stable supply in this segment. Barty Medical’s introducer sheaths stood out for strong clinical performance and reliable long-term supply, claiming the top rank in a cross-regional bulk procurement program covering Hebei and 26 other provincial-level regions, breaking the long-standing foreign monopoly. Based on 2025 revenue figures tracked by CIC, the company’s Heety® disposable catheter sheath system ranks first among domestic brands and second across all players in China’s market.

As demand for pan-vascular disease treatment keeps climbing, clinical practice in vascular intervention is shifting toward implant-free procedures, higher precision and integrated treatment regimens. Even so, unmet clinical needs remain prevalent. Permanent drug-eluting stents, for instance, are associated with common complications such as in-stent restenosis, thrombosis, stent displacement and fracture, frequent flow-limiting dissection, and poor performance in treating calcified lesions. Against this backdrop, Barty Medical stays at the forefront of technological advancement, building a diversified innovative product pipeline to address unmet clinical challenges.

In the peripheral intervention segment, Matrix Super PTX®, the company’s flagship third-generation constrained drug-coated balloon, gained regulatory approval in July 2024. Per CIC data, it is the world’s second and China’s first commercially available device of its kind. The product delivers controllable dilation while inhibiting tissue hyperplasia to prevent restenosis and thrombosis.

Outperforming conventional balloon products, Matrix Super PTX® enables more precise lesion preparation and targeted drug delivery. It improves clinical outcomes and surgical efficiency while markedly cutting the risk of post-procedure vascular dissection. The device has been adopted by hundreds of clinical centers nationwide, with monthly implantation volumes reaching hundreds and climbing steadily. It has earned wide clinical recognition and become a preferred option for implant-free peripheral vascular treatment.

For coronary intervention, Barty Medical’s breakthrough offering Matrix Crush™ coronary constrained drug-coated balloon integrates constrained balloon technology with blood perfusion functions. It addresses key pain points of traditional drug-coated balloons, including limited dilation duration and efficacy in large coronary vessels (diameter ≥2.5 mm) as well as elevated risks of flow-limiting dissection. As a world-first combination device for implant-free treatment of de novo lesions in large coronary vessels, it has completed patient enrollment for its pivotal clinical trial co-led by teams headed by Academician Ge Junbo from Zhongshan Hospital, Fudan University, and Academician Wang Jian’an from The Second Affiliated Hospital of Zhejiang University School of Medicine. Clinical follow-up will be completed in 2026. The trial uses drug-eluting stents — the gold standard therapy for large coronary de novo lesions — as the control arm, making Matrix Crush™ the world’s first third-generation drug-coated balloon to benchmark against this mainstream treatment. Upon launch, the product is expected to reshape treatment protocols for 70% of all coronary interventional procedures and serve over 10 million potential coronary heart disease patients seeking implant-free therapy in China.

On the global front, Barty Medical’s products are now sold in more than 40 countries and regions, with overseas revenue accounting for an increasingly larger share of total sales. Amid tightening global medical device regulations, the company is on track to obtain CE MDR certification for its Flowty™ coronary drug-coated balloon and Egyty™ peripheral drug-coated balloon in the second half of 2026. The two devices will be among the world’s first drug-coated balloons to secure approval under the latest EU Medical Device Regulation. Powered by these leading excipient-free drug-coated balloons, Barty Medical will build a well-rounded global product portfolio and bring Chinese medical innovations to the world. Proceeds from the latest financing will also support the company’s international collaboration efforts, global clinical data accumulation and broader global brand expansion.